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Aberrant RNA Splicing Minireview
in Sporadic Amyotrophic
Lateral Sclerosis
present in 40 control patients with other neurodegenera-
tive diseases. The aberrantly processed RNAs detected
in ALS patients are all related to EAAT2; the aberrant
transcripts and concomitant loss of EAAT2 protein were
only found in motor cortex and spinal cord; and an S1
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the majority of EAAT2 mRNA was found in aberrantlyBoston, Massachusetts 02115
processed forms in ALS patients with low EAAT2 protein
levels. Remarkably, this aberrant splicing does not ap-
In this issue of Neuron, in what will undoubtedly become pear to be the consequence of mutations within the
a landmark paper, Jeffrey Rothstein's group at Johns EAAT2 pre-messenger RNA or the EAAT2 gene. The
Hopkins reports what we believe is the first example of aberrantly spliced EAAT2 mRNAs were predominantly
a human disease associated with both aberrant RNA of two types, representing partial intron 7±retention and
splicing products and an abnormal splicing mechanism exon 9±skipping transcripts. When expressed in COS
(Lin et al., 1998 [this issue of Neuron]). Previous studies cells, transcripts with partial retention of intron 7 exerted
a dominant-negative effect on EAAT2 protein levels.of genetic diseases have shown that mutations within
Based on this evidence, the hypothesis that the major-a gene can lead to inappropriate pairing of 59 and 39
ity of sporadic cases of ALS are due to malfunctioningsplice sites resulting in exon skipping, or to the recogni-
splicing factor(s) is likely to be correct. However, ittion of ªcrypticº 59 and 39 splice sites producing aber-
should be noted that the data are correlative rather thanrantly spliced RNAs. In addition to this mechanism,
constituting proof by causation, and alternative hypoth-Rothstein and colleagues observed a second phenome-
eses could conceivably be formulated. An additionalnon: a defect in the splicing machinery (not in the gene)
problem involves testing the hypothesis by expressionthat leads to the use of inappropriate 59 and 39 splice
of transfected cDNAs in COS cells. Under these condi-sites (often called donor and acceptor sites for splicing,
tions, genes are greatly overexpressed compared torespectively). This gives rise to additional abnormal tran-
normal cells. Such overexpression can cause artifactsscripts and constitutes an apparently new concept in
in localization of proteins. The authors used this in vitrodisease pathogenesis. The disease discussed here is
expression system to show that EAAT2 mRNA under-amyotrophic lateral sclerosis (ALS or Lou Gerhig's dis-
goes rapid degradation and that the intron 7±reten-ease), with sporadic or nonfamilial patients accounting
tion RNA causes a dominant-negative effect on normalfor approximately 95% of ALS cases worldwide. Pre-
EAAT2, resulting in loss of protein and activity. Nonethe-viously, it was known that 5% of cases were inherited
less, aberrant exon 9±skipping transcripts appear to bein an autosomal-dominant manner, and z1% of cases
the most abundant in some ALS patients but have nowere due to mutations of the Cu21/Zn1 superoxide dis-
effect on overexpressed EAAT2 protein in COS cells.mutase gene (Rosen et al., 1993). The Rothstein group
Stable transfections of cells normally expressing EAAT2had already shown that 60%±70% of patients with spo-
would yield a more reliable system in which to test theradic ALS display a loss of the astrocytic glutamate
hypothesis that the aberrantly expressed transcripts af-transporter protein EAAT2 in motor cortex and spinal
fect EAAT2 activity. An even more critical test of thecord (Rothstein et al., 1995). This finding supported an
hypothesis will come from transgenic mice manifesting`excitotoxic' hypothesis for most cases of ALS, with
tissue-specific expression of the aberrant RNAs andneurons dying by overexcitation due to excessive gluta-
may offer proof of the model that aberrant splicing con-mate receptor stimulation and the resulting oxidative or
tributes to this neurodegenerative disorder. However,nitrosative stress. The important point of the paper in
examination of full-length PCR products shows that ALSthis issue of Neuron is that the data imply (but do not
patients often have many abnormal RNA species and notdefinitively prove) that there is a specific defect inEAAT2
just exon 9 skipping or intron 7 retention, so a detailedmRNA splicing in ALS tissue. This defect does not ap-
mechanistic pathogenesis is still lacking.pear to result from a mutation in the EAAT2 gene itself,
How can we understandhow abnormal mRNA splicingas seen in alleles of many other disease genes. Nor does
could arise and exactly what steps are involved? Forthe problem appear to arise from an abnormality in the
about 20 years, we have known that most genes ingeneral splicing apparatus such as the spliceosome be-
eukaryotic cells are interrupted by introns, often com-cause splicing of other non-EAAT2 transcripts is not
prised of very large sequences. During transcription,affected. Rather, the findings may imply a defect in a
DNA polymerase II transcribes an entire gene to producesplicing regulatory factor that is only required for splic-
precursor mRNA (pre-mRNA). Nascent pre-mRNA un-ing relatively few transcripts, presumably including
dergoes RNA processing; this includes precise splicingEAAT2.
out of the intronic sequences and ligating together theRothstein and colleagues report the presence of aber-
sequences encoded by exons that on average are muchrant RNAs in 65% of sporadic ALS cases based on
smaller (mean, 137 bp per exon) (Berget, 1995). Splicingexaminations of 30 patients. Aberrant RNAs were not
occurs concurrently with transcription. The splicing re-
action is carried out by the spliceosome, a multicompo-
nent complex containing over 70 proteins and 5 small* To whom correspondence should be addressed.
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Figure 1. Schematic Representation of Normal and Abnormal Alternative mRNA Splicing
(A) Model summarizing alternatively spliced mRNA patterns caused by physiological regulation of splice-related sequences. Generally, cleavage
and ligation follow the so-called ªGT-AG ruleº (involving GU and AG sites on pre-mRNA; see text for explanation).
(B) Model summarizing alternatively spliced mRNA patterns caused by pathological mutation of splice-related sequences or possibly from a
defect in a splicing regulatory factor(s). Normal 59 and 39 splice sites may be ªskipped over,º resulting in exon deletion or partial intron retention
as occur in the predominant aberrant EAAT2 mRNAs from patients with sporadic ALS. Additionally, in other diseases, aberrant mRNAs are
generated by cleavage and ligation using cryptic sites following the GT-AG rule (see text).
(C) Deletion pattern of some abnormal EAAT2 mRNAs (labeled #1±#6 from ALS Case #3 of Lin et al., 1998). These inappropriate EAAT2 mRNAs
are not cleaved and ligated following the GT-AG rule. Blue boxes represent exonic sequences and yellow boxes indicate ligated intronic
(pseudo-exonic) sequences. Sequences that have been spliced out are represented by caret or inverted caret-like lines. Terminal invariant
(A and B) or random (C) dinucleotides for the 59 donor and 39 acceptor sites are listed.
nuclear RNAs (Will and LuÈ hrmann, 1997). The spliceo- Alternative RNA splicing can produce physiological
variants in proteins by selectively including or excludingsome is assembled in a stepwise manner, and the cor-
rect 59 and 39 splice sites are recognized by specific particular exons. Sequences flanking the splice donor
and acceptor sites or located in neighboring introns orcomponents of the spliceosome during the earliest
stage of spliceosome assembly. The 59 donor splice site exons can influence the activity of the splice sites (Reed,
1996). A ªweakº site may result in exon skipping (exclu-includes an initial intronic dinucleotide that is invariant
(GT [or GU if considering the pre-mRNA sequence]); the sion) (Berget, 1995). Pre-mRNA splicing is a highly regu-
lated process. Recent findings indicate that cis elements39 acceptor splice site has an intronic sequence ending
in the invariant dinucleotide AG (Figure 1A). Spliceo- located in exons and introns, termed exonic splicing
enhancers (or ESEs) and intronic splicing enhancers (orsome assembly is a dynamic process, ultimately leading
to the accurate positioning of the 59 and 39 splice sites ISEs), interact with trans-acting factors (e.g., activators)
to regulate the recognition of splice sites and the ratefor cleavage of the intron and ligation of the exons (Sta-
ley and Guthrie, 1998). Assembly of the spliceosome of the splicing. However, not all splicing regulator se-
quences are splicing enhancers, for example, those thatbegins on the RNA as it is synthesized. After other RNA
processing events occur in the nucleus (e.g., 59 capping, bind repressor proteins. SR (serine-arginine±rich) pro-
teins and other RNA binding proteins are involved in39 polyadenylation, and editing), mRNA is ªmatureº and
ready for exportation into the cytoplasm to serve as a the regulation of alternative splicing and serve as trans
factors (Cooper and Mattox, 1997; Wang and Manley,template for translation. Recently, a small group of in-
trons has been found to have different consensus dinu- 1997).
Single mutations of the invariant dinucleotides orcleotides at 59 splice donor and 39 acceptor sites (AT [or
AU for pre-mRNA] and AC, respectively). Their splicing flanking sequences of splice sites may change the pat-
tern of splicing (Nakai and Sakamoto, 1994; Berget,involves the same reactions as the majority of introns,
but uses different small nuclear RNAs (Tarn and Steitz, 1995; Cooper and Mattox, 1997). Mutations of ESEs or
ISEs may also change the splicing pattern (Cooper and1997). All of these proteins represent potential targets
for disease processes. One example is SMN (survival Mattox, 1997). Hence, genomic mutations (point muta-
tions, insertions, or deletions) of these splice-relatedmotor neuron) protein, apparently involved in assembly
of the small nuclear RNAs, which has recently been donor, acceptor, and enhancer site sequences can
cause abnormal alternative splicing. In fact, several hu-found to be lost in another motor neuron disease, spinal
muscular atrophy (Liu et al., 1997). man diseases have been shown to be caused or at least
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correlated with the loss of functional protein activity In sporadic cases of ALS, why does the aberrant RNA
due to abnormal splice variants arising from genetic or processing occur only in EAAT2 pre-mRNA, and why
somatic mutations of splice-related sequences (Nakai only in the motor cortex and spinal cord? There are as
and Sakamoto, 1994; Cooper and Mattox, 1997). As an yet no clear answers to these questions. We know that
example of a genetic disease, historically the first splic- motoneurons are very active metabolically and therefore
ing mutations recognized were found in the b-globin could be readily subjected to oxidative or nitrosative
gene of patients with b-thalassemia, some of which re- stress. A unifying hypothesis might therefore invoke
sult in the activation of cryptic splice sites producing stress-related damage to the aforementioned protein(s)
either partial exon deletion or intron retention (Treisman responsible for RNA splicing. However, it is an astrocytic
et al., 1983). Patients with hereditary vitamin D±resistant glutamate transporter rather than a neuronal transporter
rickets display inherited mutations in the donor splice that is affected, so the link to neuronal stress is not a
site on intron 4 of the vitamin D3 receptor gene. This direct one. Moreover, why such a mechanism should
mutation causes skipping of exon 4 and results in a specifically affect EAAT2 mRNAs while leaving tran-
nonfunctional receptor for vitamin D. Another example scripts encoding other proteins unaffected remains a
is a somatic mutation of the genome encoding the P53 mystery. Alternatively, some additional mRNAs whose
gene in some patients with liver cancer. Additionally, a splicing is abnormally regulated by damage to a specific
nonsense mutation of an ESE in the dystrophin gene splice-related factor could be affected in these sporadic
causing upstream exon skipping results in Becker mus- cases of ALS, and we just do not know the identity of
cular dystrophy (Shiga et al., 1997). These diseases all these other mRNAs as yet.
appear to be produced by mutations in the splice- Finally, in at least one of Rothstein's ALS patients
related sequences but use a normal mechanism of splic- (Case #3) with abnormal EAAT2 RNAs, several of the
ing (Figure 1B). In contrast, the Rothstein group mounts PCR products were found to migrate on agarose gels
evidence that ALS is associated with an abnormal splic- as a single band but actually represented a mixture of
ing process for EAAT2 pre-mRNA that can skip normal RNAs. Thus, the presence of a ªnormalº level of mRNA
59 donor and 39 acceptor sites (Figure 1B, top half) or evidenced by a single band on a Northern blot or RT±
utilize inappropriate 59 and 39 splice sites (i.e., other than PCR in the face of a low level of cognate protein does
the normal GU or AU for the donor site, and AG or AC not exclude an abnormal mechanism of RNA processing.
for the acceptor site) (Figure 1C). In addition to aberrant
This raises the possibility that in other diseases the
partial intron-retention and exon-skipping transcripts,
presence of multiple abnormal RNAs could easily be
this abnormal splicing mechanism results in the appear-
overlooked.
ance of EAAT2 mRNAs that have been cleaved and
In summary, many cases of sporadic ALS are corre-
ligated in exonic sequences at random sites. In other
lated with aberrant RNAs caused by ignoring apparently
words, previously, we knew that normal splicing could
normal 59 and 39 splice sites, resulting in exon skippingresult in aberrant RNAs and thus disease. The Rothstein
and partial intron retention, and, to some extent, inap-findings extend our knowledge by showing that an ab-
propriate RNAs due to an abnormal splicing mechanismnormal mechanism of splicing can also appear in a dis-
using random 59 and 39 splice sites. Further proof thateased state. The malfunction in the splicing mechanism
this represents a pathogenesis of ALS using transgenicassociated with ALS gives rise to multiple abnormal
mice is anxiously awaited, e.g., expression of a partialRNAs in any given patient (Figures 1B and 1C). In con-
intron 7±retention mutant producing a dominant-nega-trast, previously identified diseases associated with
tive effect on EAAT2. However, final elucidation of thesplice variants have encountered only a single or at most
molecular pathogenesis of sporadic ALS may come nottwo aberrant RNAs in an affected patient (Nakai and
from the expression of a single aberrant mRNA thatSakamoto, 1994; Cooper and Mattox, 1997). The most
reproduces the phenotype, but in cloning the postulatedimportant point in the case of sporadic ALS is that there
defective splicing regulatory factor and expressing it inseems to be a problem not in the EAAT2 gene itself
transgenic mice. This approach should provide recapit-that gives rise to the aberrant splicing, but instead in a
ulation of all of the features of the disease, includingregulatory factor(s) that appears to beat least somewhat
the interesting pattern of aberrant mRNAs present inspecific for EAAT2 transcripts.
any single patient.Aberrant RNAs have become so abundant that Nakai
and Sakamoto in 1994 established an aberrant splic-
ing database (Web site: http://www.imcb.osaka-u.ac.jp/ Acknowledgments
nakai/asdb.html). They have collected more than 200
splice site mutations in 90 genes, most of them associ- We wish to thank the anonymous referees of this review
ated with human disease (Nakai and Sakamoto, 1994). who contributed greatly to the clarity of its message
Exon skipping accounted for 50% of the mutations, (and hopefully avoided aberrancy).
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